Sign-out with Dr. Haas was never casual. James sat across from her at the double-headed scope. The slides were already lined up. Dictation sheets squared to the edge of the desk. Nothing out of place. He checked them again anyway.
“Next case,” she said.
“Forty-five-year-old male,” James began. “Rapidly enlarging mass, anterior thigh. Six weeks’ duration. Outside diagnosis favors fibrosarcoma.”
Haas adjusted the oculars. “Show me.”
James rotated the slide under low power.
“The lesion is intramuscular. Highly cellular. Short intersecting fascicles.”
No response. He increased magnification.
“Mitotic activity is present. No atypical mitoses. Minimal necrosis.”
He shifted the field.
“There’s focal myxoid change. And here—” a small adjustment, just enough, “—areas with a tissue-culture appearance.”
Haas didn’t look up.
“What does that mean?”
James paused a fraction longer than usual.
“The cells are more loosely arranged,” he said. “Reactive in pattern. Not structurally malignant.”
He moved again.
“The history notes rapid growth. Painful. No prior lesion. The surgeon describes the mass as well circumscribed.”
He stopped there. Let it sit.
Haas leaned back slightly. “And your diagnosis?”
“Nodular fasciitis.”
She pulled away from the scope.
“Not fibrosarcoma.”
“No.”
“Why not?”
James felt it then—not doubt. The weight of the room narrowing. He didn’t rush.
“Because the architecture doesn’t behave like a sarcoma,” he said. “There’s variation, but not the kind that loses control. I’m not seeing atypical mitoses. No convincing herringbone pattern. The borders push. They don’t infiltrate.”
He shifted slightly.
“And the growth is fast,” he added. “Faster than most sarcomas present.”
Haas watched him. “You understand surgery will be uncomfortable with that call.”
“Yes.”
“And you’re prepared to defend it.”
“Yes.”
That part came easier than he expected. She held his gaze a moment longer.
“Call Dr. McIntyre.”
James hesitated just enough to feel it. “Now?”
“Yes.”
Scott arrived quickly. No greeting. No delay.
“You wanted to review the thigh mass?”
“Yes,” Haas said. “Dr. Deetan favors nodular fasciitis.”
Scott’s attention sharpened immediately. “That lesion was eight centimeters.”
James nodded. “And it grew over six weeks.”
Scott stepped in, took the scope. He didn’t speak for a while.
“It’s cellular,” he said finally.
“Yes.”
“It’s mitotically active.”
“Yes.”
Scott turned slightly. “And you’re comfortable telling the surgeon this is benign?”
James met his eyes. “I’m comfortable telling him it is not fibrosarcoma.”
A small difference. It felt larger than it sounded. Scott went back to the slide.
“Show me.”
James leaned in, adjusted the field.
“Here. The periphery—see how it organizes. And here—more myxoid stroma. And here…”
He paused just long enough to center it.
“…extravasated red blood cells.”
Scott stayed quiet.
“That doesn’t exclude malignancy.”
“No,” James said. “It doesn’t.”
He didn’t add anything else. Didn’t need to. Scott straightened.
“You’re leaning heavily on the history.”
“I’m using it.”
The familiar tightening started in his chest. Not panic. Recognition. Rooms like this had memory. What you said stayed longer than you expected.
Haas stepped in. “Dr. McIntyre, are you advocating sarcoma?”
Scott didn’t answer immediately. “I’m advocating caution.”
Haas didn’t shift. “So is he.”
She moved to the scope. The room went still again. Only the faint hum of the scope. James watched her—not the slide, but her pace. No hesitation. No searching for confirmation. Just… review.
After a few minutes, she leaned back. “I agree with Dr. Deetan.”
Scott didn’t move. Haas continued.
“Overcalling a reactive lesion as malignant carries consequences.”
She didn’t raise her voice.
“Treatment. Follow-up. Years of being labeled something you are not.”
Scott’s jaw tightened. He didn’t argue. Haas turned back to James.
“You will document the rationale clearly. Clinical tempo. Growth pattern. Histologic features.”
“Yes.”
“If it recurs, we re-evaluate.”
“Yes, Dr. Haas.”
Scott looked between them. “If it proves malignant later—”
“We will follow it,” Haas said.
That was the end of it. Scott left. The room felt different after he did. James noticed that.
Because of the disagreement, Haas scheduled a formal review. That alone told everyone it mattered. The conference room filled quickly. Susan sat in the front, already writing. Scott stood off to the side. Nomura stayed in the back. Watching.
Haas projected the images.
“Let’s review the thigh lesion.”
No mention of disagreement. Just the case. James presented again. Slower this time. More deliberate. He didn’t feel rushed. That surprised him.
Susan raised her hand. “Would proliferative myositis be in the differential?”
“Yes,” James said. “But the ganglion-like cells aren’t prominent here.”
Scott spoke without moving forward. “Would you send this out?”
Haas answered. “Not at this time.”
She looked at the room. “You will see lesions that look malignant. Your job is not to react. Your job is to understand what you’re looking at.”
Her eyes moved—briefly—to Scott. Then away. No one missed it. Nomura didn’t look at Haas. He watched James. Not the answer. The way he held it. That was what mattered.
The session ended without much discussion. People gathered their things quietly. The case was over. It didn’t feel over. James stayed a moment longer than he needed to. Not thinking. Just… settling. Susan didn’t leave right away. The images were still on the screen. She flipped open her notebook. There was something about the frozen case that hadn’t sat right. Not the diagnosis. The sequence. She wrote two words.
Verify timestamps.
She looked at it for a second. Then closed the notebook.